5M0B Stock Chart & Stats
€23.05
-€0.76(-4.50%)
At close: 4:00 PM EST
€23.05
-€0.76(-4.50%)
Day’s Range― - ―
52-Week Range€16.74 - €23.90
Previous CloseN/A
Volume0.00
Average Volume (3M)152.00
Market Cap
€3.25B
Enterprise Value€50.31K
Total Cash (Recent Filing)€92.70M
Total Debt (Recent Filing)€1.46B
Price to Earnings (P/E)38.4
Beta0.71
Next Earnings
Nov 04, 2026EPS Estimate
0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.56
Shares Outstanding75,424,480
10 Day Avg. Volume239
30 Day Avg. Volume152
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)5.74
Price to Sales (P/S)1.29
P/FCF Ratio16.48
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.06
Revenue Forecast (FY)€232.34M
Bulls Say, Bears Say
Bulls Say
Double-digit Organic Revenue GrowthBroad-based double-digit organic growth across Healthcare and Diagnostics indicates sustained demand and expanding operating scale. Continued volume and service adoption can strengthen Medicover’s network economics, support reinvestment, and provide a durable foundation for earnings growth over the next several quarters.
Margin Expansion And Operating EfficiencyImproving margins across multiple quarters suggest that growth is translating into better operating efficiency rather than relying solely on higher revenue. This supports stronger earnings quality, improves resilience against cost pressure, and gives management more capacity to fund expansion while pursuing its 2028 targets.
Positive Cash Generation And Lower LeverageRising operating cash flow and positive free cash flow provide internal funding for investment and debt service. At the same time, leverage below 3x and the year-on-year reduction improve financial flexibility, making the business better positioned to support growth and absorb operational volatility.
Bears Say
Leverage Remains ElevatedAlthough leverage has improved recently, debt remains high relative to equity and still constrains financial flexibility. A weaker operating period or higher financing costs could place greater pressure on cash available for expansion, dividends, and debt reduction, limiting strategic room over the medium term.
India Expansion Is Currently Margin DilutiveThe Indian hospital rollout offers growth but currently consumes earnings through start-up losses, particularly while large new facilities mature. If ramp-up takes longer than planned, continued dilution could offset group margin gains and require sustained investment before the expansion contributes positively to profitability.
Reimbursement And Working-capital PressureDependence on government-funded payment systems exposes parts of the business to tariff, budget, and policy changes that can alter revenue mix and timing. Longer collection periods also tie up cash, potentially reducing conversion of accounting profits into funds available for investment and debt service.
Medicover AB News
5M0B FAQ
What was Medicover AB’s price range in the past 12 months?
Medicover AB lowest stock price was €16.74 and its highest was €23.90 in the past 12 months.
What is Medicover AB’s market cap?
Medicover AB’s market cap is €3.25B.
When is Medicover AB’s upcoming earnings report date?
Medicover AB’s upcoming earnings report date is Nov 04, 2026 which is in 48 days.
How were Medicover AB’s earnings last quarter?
Medicover AB released its earnings results on Jul 22, 2026. The company reported €0.17 earnings per share for the quarter, beating the consensus estimate of €0.165 by €0.005.
Is Medicover AB overvalued?
According to Wall Street analysts Medicover AB’s price is currently Overvalued.
Does Medicover AB pay dividends?
Medicover AB does not currently pay dividends.
What is Medicover AB’s EPS estimate?
Medicover AB’s EPS estimate is 0.18.
How many shares outstanding does Medicover AB have?
Medicover AB has 75,424,480 shares outstanding.
What happened to Medicover AB’s price movement after its last earnings report?
Medicover AB reported an EPS of €0.17 in its last earnings report, beating expectations of €0.165. Following the earnings report the stock price went down -0.706%.
Which hedge fund is a major shareholder of Medicover AB?
Currently, no hedge funds are holding shares in DE:5M0B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Medicover AB
Established in 1995 and headquartered in Stockholm, Sweden, Medicover AB (publ) is a prominent international provider of both healthcare and diagnostic services. The company operates across numerous countries, including Germany, Sweden, Poland, Turkey, Belarus, Bulgaria, Georgia, Hungary, Serbia, Moldova, Ukraine, and India. It is structured into two main divisions: Healthcare Services and Diagnostic Services. Through its diagnostic division, Medicover performs a comprehensive array of specialized tests, which include analyses for allergy and autoimmune conditions; bacteriology and parasitology; biochemistry and immunochemistry; blood group diagnostics and transfusion medicine; tumour markers; clinical chemistry; cellular analyses like cytology, haematology, and histopathology; human genetics; hygiene; general immunology; infectious diseases; microbiology; molecular biology; and pharmacology/toxicology. Medicover maintains a substantial operational footprint, encompassing 97 clinical laboratories, 733 blood-drawing points, and 26 clinics dedicated to diagnostic services across 10 countries. Its healthcare segment further comprises 117 medical clinics, 20 fertility clinics, 52 dental clinics, 25 hospitals, and 25 gyms. The company caters to a broad customer base, serving corporate entities, private individuals, direct patients, and public sector payers.